Buscar

Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

Activity of ceftazidime-avibactam against clinical and isogenic laboratory pseudomonas aeruginosa isolates expressing combinations of most relevant ß-Lactam resistance mechanisms

Abstract: The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at =4 µg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant ß-lactam resistance mechanisms.

 Fuente: Antimicrob Agents Chemother, 2016, 60(10), 6407-6410

Editorial: American Society for Microbiology

 Año de publicación: 2016

Nº de páginas: 4

Tipo de publicación: Artículo de Revista

 DOI: 10.1128/AAC.01282-16

ISSN: 0066-4804,1098-6596,1070-6283

Autoría

TORRENS, GABRIEL

CABOT, GABRIEL

OCAMPO SOSA, ALAIN A.

CONEJO, M. CARMEN

ZAMORANO, LAURA

NAVARRO, FERRAN

PASCUAL, ALVARO

LUIS MARTINEZ MARTINEZ

OLIVER, ANTONIO